Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ-Reference-Cited by-同舟云学术

Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ

Published:2020-07-17 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Waddington Kirsty E.,Papadaki Artemis,Coelewij Leda,Adriani Marsilio,Nytrova Petra,Kubala Havrdova Eva,Fogdell-Hahn Anna,Farrell Rachel,Dönnes Pierre,Pineda-Torra Inés,Jury Elizabeth C.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference72 articles.

1. Treatment of multiple sclerosis — success from bench to bedside;Tintore;Nat Rev Neurol.,2019

2. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis;Sorensen;Lancet,2003

3. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study;Kappos;Neurology,2005

4. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity;Hesse;Neurology,2009

5. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis;Vennegoor;Mult Scler.,2013

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity;Clinical Immunology;2024-10

2. Role of metabolomics in precision medicine in the context of systemic lupus erythematosus and lupus nephritis;Personalized Medicine - New Perspectives [Working Title];2024-06-24

3. Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis;Clinical and Experimental Immunology;2024-04-16

4. Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity;iScience;2024-03

5. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11